Amino Acid Metabolism Disorders Therapeutics
1. Kuvan patent expiration
Treatment: Kuvan is indicated to reduce blood phenylalanine levels in patients with hyperphenylalaninemia; To reduce blood phenylalanine (phe) levels in patients with hyperphenylalaninemia (hpa); Method of use f...
KUVAN's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| USRE43797 | BIOMARIN | Methods of administering tetrahydrobiopterin |
Nov, 2024
(1 year, 3 months ago) | |
|
US7947681 (Pediatric) | BIOMARIN | Methods of administering tetrahydrobiopterin, associated compositions, and methods of measuring |
May, 2025
(9 months ago) | |
| US7947681 | BIOMARIN | Methods of administering tetrahydrobiopterin, associated compositions, and methods of measuring |
Nov, 2024
(1 year, 3 months ago) | |
| US7566714 | BIOMARIN | Methods and compositions for the treatment of metabolic disorders |
Nov, 2024
(1 year, 3 months ago) | |
|
US9433624 (Pediatric) | BIOMARIN | Methods and compositions for the treatment of metabolic disorders |
May, 2025
(9 months ago) | |
| US7612073 | BIOMARIN | Methods of administering tetrahydrobiopterin, associated compositions, and methods of measuring |
Nov, 2024
(1 year, 3 months ago) | |
| US9433624 | BIOMARIN | Methods and compositions for the treatment of metabolic disorders |
Nov, 2024
(1 year, 3 months ago) | |
| US8067416 | BIOMARIN | Methods and compositions for the treatment of metabolic disorders |
Nov, 2024
(1 year, 3 months ago) | |
| US8003126 | BIOMARIN | Stable tablet formulation |
Nov, 2025
(3 months ago) | |
| US7566462 | BIOMARIN | Stable tablet formulation |
Nov, 2025
(3 months ago) | |
| US7727987 | BIOMARIN | Crystalline forms of (6R)-L-erythro-tetrahydrobiopterin dihydrochloride |
Nov, 2024
(1 year, 3 months ago) | |
| US8318745 | BIOMARIN | Crystalline forms of (6R)-L-erythro-tetrahydrobiopterin dihydrochloride |
Nov, 2024
(1 year, 3 months ago) | |
| US9216178 | BIOMARIN | Dry blend formulation of tetrahydrobiopterin |
Nov, 2032
(6 years from now) | |
|
US7566462 (Pediatric) | BIOMARIN | Stable tablet formulation |
May, 2026
(2 months from now) | |
|
US7566714 (Pediatric) | BIOMARIN | Methods and compositions for the treatment of metabolic disorders |
May, 2025
(9 months ago) | |
|
US7612073 (Pediatric) | BIOMARIN | Methods of administering tetrahydrobiopterin, associated compositions, and methods of measuring |
May, 2025
(9 months ago) | |
|
US7727987 (Pediatric) | BIOMARIN | Crystalline forms of (6R)-L-erythro-tetrahydrobiopterin dihydrochloride |
May, 2025
(9 months ago) | |
|
US8003126 (Pediatric) | BIOMARIN | Stable tablet formulation |
May, 2026
(2 months from now) | |
|
US8067416 (Pediatric) | BIOMARIN | Methods and compositions for the treatment of metabolic disorders |
May, 2025
(9 months ago) | |
|
US8318745 (Pediatric) | BIOMARIN | Crystalline forms of (6R)-L-erythro-tetrahydrobiopterin dihydrochloride |
May, 2025
(9 months ago) | |
|
USRE43797 (Pediatric) | BIOMARIN | Methods of administering tetrahydrobiopterin |
May, 2025
(9 months ago) | |
|
US9216178 (Pediatric) | BIOMARIN | Dry blend formulation of tetrahydrobiopterin |
May, 2033
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 13, 2012 |
| Orphan Drug Exclusivity(ODE) | Dec 13, 2014 |
| New Patient Population(NPP) | Apr 23, 2017 |
| Pediatric Exclusivity(PED) | Oct 23, 2017 |
Drugs and Companies using SAPROPTERIN DIHYDROCHLORIDE ingredient
NCE-1 date: 23 October, 2016
Market Authorisation Date: 13 December, 2007
Dosage: TABLET; POWDER
How can I launch a generic of KUVAN before it's drug patent expiration?
More Information on Dosage
KUVAN family patents
